CONTEXT: Large scale ophthalmic registry results re-enforce the need for early detection and treatment of age-related macular degeneration (AMD) | US data only, American Academy of Ophthalmology IRIS registry is the source data | As someone with bilateral retinopathy, it’s always good to see progress in this field. It’s slow, but it’s happening.
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 8
1. “The study used the American Academy of Ophthalmology IRIS Registry, one of the largest clinical databases worldwide, to quantify baseline visual acuity in patients initiating intravitreal injection treatment for AMD and to determine how baseline visual acuity correlated with long-term visual outcomes in real-world settings.”
2. “Of the 21,838 patients who were diagnosed with wet AMD in the second eye, only 36% had a visual acuity of 20/40 or better as compared with 33.3% of first eyes, even though patients were, presumably, already taken care of by a retina specialist.”
3. ““Current methods of home monitoring, such as the classic Amsler grid, clearly fail to detect wet AMD early enough to maintain good vision in over 65% of patients, as shown by our study,” Ho said.”
4. “In the AREDS2-HOME study, 94% of patients who used home monitoring in addition to standard care had 20/40 or better vision when wet AMD was first detected.”
5. ““This was a clinical trial, but real-world data collected since the approval of ForeseeHome have shown that 83% of the patients are detected when vision is 20/40 or better, which is two and a half times more than in the IRIS Registry,” Ho said.”